Evidence map›Paper›PMID 41508057›Full record

SynthesisOrphanet journal of rare diseases2026

Swallowing and feeding after disease-modifying treatment for spinal muscular atrophy: a systematic review of assessment modalities and outcomes.

Yasmina Martí, Ksenija Gorni, Sandhya Kumari, Anadi Mahajan, Giovanni Baranello, Liesbeth De Waele, Katlyn E McGrattan

Abstract readSystematic ReviewReview
In one paragraph

Synthesis in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yasmina MartíF. Hoffmann-La Roche Ltd, Basel, Switzerland. yasmina.marti_gil@roche.com.ORCID http://orcid.org/0000-0002-9057-8599
Ksenija GorniF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Sandhya KumariBridge Medical Consulting Ltd, Richmond, London, UK.
Anadi MahajanBridge Medical Consulting Ltd, Richmond, London, UK.
Giovanni BaranelloThe Dubowitz Neuromuscular Centre, National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health University College London, and Great Ormond Street Hospital Trust, London, UK.
Liesbeth De WaeleNMRC for Children, Department of Paediatrics, University Hospitals Leuven, Leuven, Belgium.
Katlyn E McGrattanDepartment of Speech-Language-Hearing Science, University of Minnesota, Minneapolis, Mn, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFeeding and swallowing deficits are reported across the spectrum of spinal muscular atrophy (SMA), with more profound symptoms associated with more severe disease. Patients treated with disease-modifying therapies (DMTs) demonstrate significantly improved life expectancy and motor function relative to untreated counterparts; however, limited data exist regarding the impact of DMTs on bulbar integrity, with evidence suggesting bulbar symptoms may persist, even when motor function has improved. This systematic literature review was conducted to identify assessments used to evaluate swallowing in patients with SMA treated with DMTs, and to describe the impact of DMTs on swallowing and feeding outcomes. Embase, MEDLINE, and Cochrane central were searched from May 2021 to February 2024 for studies reporting swallowing and feeding outcomes in patients treated with nusinersen, onasemnogene abeparvovec, and risdiplam.

resultsSeventy-one studies were included. The majority of studies (99%, n = 71) reported functional swallow outcomes, such as oral intake status or patient-reported outcomes, and only 19% reported results from clinician-administered assessments. Results from imaging assessments were rarely reported (5%, n = 4 studies). Only 68% of studies reported results from both pre- and post-treatment assessments. Patients who received DMT prior to symptom onset were found to have good functional outcomes, with 84–100% receiving full oral nutrition. Treatment after symptom onset yielded variable results, with trends suggesting that treatment outcomes are influenced by the level of impairment at baseline and the type of swallowing assessment used. The ability to maintain pre-treatment swallow integrity was variable across studies.

conclusionAlthough evidence suggests that DMTs can preserve or improve bulbar function in SMA, swallowing and feeding are not regularly or homogeneously assessed across the literature, making comparisons across studies difficult. Standardised and validated assessments of swallowing physiology and swallowing function are needed to understand what factors may influence bulbar outcomes with DMTs.

Indexed as

DeglutitionMuscular Atrophy, SpinalDeglutition DisordersHumansOligonucleotidesTreatment OutcomenusinersenOligonucleotidesBulbar functionFeedingNusinersenOnasemnogene abeparvovecRisdiplamSpinal muscular atrophySwallowingSystematic literature review

Identifiers

PMID41508057
PMCPMC12781761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.